Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

EQ
Equillium, Inc. Common Stock
stock NASDAQ

At Close
Jul 2, 2026 3:59:42 PM EDT
2.91USD-4.112%(-0.13)3,058,395
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 2, 2026 9:06:30 AM EDT
2.98USD-1.974%(-0.06)2,752
After-hours
Jul 2, 2026 4:56:30 PM EDT
2.91USD-0.099%(0.00)72,030
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
08:28AM EST  Equillium Highlights Multiple Abstracts For Presentation At Transplantation, Cellular Meetings Feb 2-6, 2022   Benzinga
Jan 5, 2022
07:17AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
06:37AM EST  SVB Leerink Maintains Outperform on Equillium, Lowers Price Target to $14   Benzinga
Jan 4, 2022
08:20AM EST  Equillium Highlights Publication Of Data In 'Journal Of Clinical Investigation' Showing Importance Of CD6-ALCAM Pathway In Pathogenesis Of Lupus Nephritis   Benzinga
08:16AM EST  Equillium Announces Data From Phase 1b EQUIP Study In Patients With Uncontrolled Asthma; Says Study Achieved Primary Objective Of Safety And Tolerability, Demonstrated Rapid And Sustained Reduction In Levels Of Cell Surface CD6   Benzinga
Dec 13, 2021
08:04AM EST  Equillium Highlights ASH Poster Presentations   Benzinga
Nov 10, 2021
04:17PM EST  Equillium Q3 EPS $(0.35) Down From $(0.31) YoY   Benzinga
Nov 5, 2021
09:42AM EDT  Equillium Highlights Presentation Of Interim Safety Data From First Cohort Of Asthma Patients In Phase 1b EQUIP Study At American College Of Allergy, Asthma, Immunology Meeting Friday At 6:45 p.m. EDT   Benzinga
Nov 2, 2021
11:24AM EDT  Equillium Reveals Early Safety Data For Itolizumab In Lupus Patients   Benzinga
10:54AM EDT  Equillium Announces Interim Safety Data And Reduction In Proteinuria For Lupus Patients Treated With Itolizumab In The EQUALISE Study Presented At The ACR Annual Meeting   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 18, 2021
08:09AM EDT  Equillium Announces Two Abstracts Accepted For Presentation At The Upcoming Virtual 2021 American Society Of Nephrology Annual Meeting   Benzinga
Oct 11, 2021
08:35AM EDT  Small Cap Growth Investor Presentations Now Available for On-Demand Viewing   PR Newswire
Oct 6, 2021
03:42PM EDT  EQ Works to Present at the Small Cap Growth Conference   PR Newswire
Sep 30, 2021
08:28AM EDT  Live Investor Conference & Webinar: Small Cap Growth Conference on October 7th   PR Newswire
Sep 15, 2021
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021   Benzinga
07:24AM EDT  Cantor Fitzgerald Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $14   Benzinga
Aug 12, 2021
07:48AM EDT  Equillium's Itolizumab Reduces Urine Protein In Lupus Patients   Benzinga
Aug 11, 2021
04:01PM EDT  Equillium Offers Added Data From EQUALISE Type A Portion Of Study In Systemic Lupus Erythematosus Patients   Benzinga
Aug 10, 2021
04:10PM EDT  Equillium Reports Q2 Loss Per Share Of $0.31 Vs. Loss Per Share Of $0.37 Last Year   RTTNews
04:02PM EDT  Equillium Q2 EPS $(0.31) Up From $(0.37) YoY   Benzinga
04:01PM EDT  Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update   Business Wire
Jul 13, 2021
09:10AM EDT  Equillium's Single Phase 3 Study In aGVHD To Support US Filing Of Itolizumab   Benzinga
08:05AM EDT  The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data   Benzinga
Jul 12, 2021
04:01PM EDT  Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA   Benzinga
Jun 11, 2021
09:53AM EDT  Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients   Benzinga
07:04AM EDT  Equillium Reports Topline Results From EQUATE Study In First-Line Treatment Of Acute Graft-Versus-Host Disease   Benzinga
07:00AM EDT  Itolizumab continues to demonstrate favorable safety and efficacy profile   GlobeNewswire Inc
Jun 10, 2021
08:03AM EDT  Equillium Highlights Presentation Of Data On Target Engagement, Modulation Of CD6 On T Cells With Itolizumab At Int'l. Society For Advancement Of Cytometry   Benzinga
08:00AM EDT  Equillium Presents Data on Target Engagement and Modulation of CD6   GlobeNewswire Inc
Jun 9, 2021
08:00AM EDT  Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conference, a virtual investor event, taking place June 16 and 17, 2021.   GlobeNewswire Inc
Jun 7, 2021
08:13AM EDT  Equillium Says To Collaborate With Oxford University, Kennedy Institute Of Rheumatology To Investigate Role Of CD6-ALCAM Pathway, Itolizumap In Rheumatic Diseases   Benzinga
08:00AM EDT  Equillium to Collaborate with Oxford University and Kennedy   GlobeNewswire Inc
Jun 3, 2021
08:00AM EDT  Presentation and conference call will include topline data from all cohorts   GlobeNewswire Inc
May 26, 2021
08:00AM EDT  Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the Jefferies Virtual Healthcare Conference taking place June 1 4, 2021.   GlobeNewswire Inc
May 17, 2021
08:00AM EDT  Research highlights itolizumabs novel mechanism of action and its effect on modulating T cell responses through inhibition of the CD6-ALCAM pathway   GlobeNewswire Inc
May 13, 2021
04:22PM EDT  Equillium Q1 EPS $(0.33) Up From $(0.45) YoY   Benzinga
04:02PM EDT  Announced favorable data from Phase 1b EQUALISE study in patients with systemic lupus erythematosus   GlobeNewswire Inc
08:01AM EDT  Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association   Benzinga
08:00AM EDT  Equillium Announces Oral Presentation Highlighting Positive Data   GlobeNewswire Inc
Apr 27, 2021
08:06AM EDT  Equillium Announces 3 Abstracts Accepted For Presentation At 104th Annual Meeting Of American Association Of Immunologists   Benzinga
08:00AM EDT  Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that three posters will be presented at VIRTUAL IMMUNOLOGYTM, the 2021 American Association of Immunologists (AAI) Annual Meeting to be held May 10-15, 2021.   GlobeNewswire Inc
Mar 31, 2021
07:44AM EDT  Equillium's Itolizumab Shows Encouraging Safety, Tolerability Profile In Systemic Lupus Erythematosus Study   Benzinga
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Mar 30, 2021
04:03PM EDT  Equillium Announces Clinical Data On Its Phase 1b EQUALISE Study In Systemic Lupus Erythematosus Patients   Benzinga
04:01PM EDT  Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus   GlobeNewswire Inc
Mar 24, 2021
04:10PM EDT  Equillium Q4 EPS $(0.36) Up From $(0.44) YoY   Benzinga
04:05PM EDT  Equillium Reports Fourth Quarter and Full Year 2020 Financial   GlobeNewswire Inc
Mar 15, 2021
10:00AM EDT  Equillium's Stock Is Trading Higher On Itolizumab's Durable, Sustained Response In Graft-Versus-Host Disease Study   Benzinga
08:31AM EDT  Equillium Announces Data For Itolizumab In Acute Graft-Versus-Host Disease In 2 Presentations At 47th Annual Meeting Of European Society For Blood And Marrow Transplantation   Benzinga
08:00AM EDT  EQUATE acute graft-versus host disease (aGVHD) study observedrapid response and durability through day 85   GlobeNewswire Inc
Mar 3, 2021
10:02AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2021   Benzinga
09:29AM EST  JonesTrading Initiates Coverage On Equillium with Buy Rating, Announces Price Target of $14   Benzinga
Mar 2, 2021
08:00AM EST  Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on March 9, 2021 at 7 am EST.   GlobeNewswire Inc
Feb 18, 2021
08:00AM EST  Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the SVB Leerink 10th Annual Global Healthcare Conference taking place February 22 26, 2021.   GlobeNewswire Inc
Feb 12, 2021
03:00PM EST  Higher dose cohorts demonstrated 100% overall response rate, resulting in substantialreduction in baseline corticosteroid use   GlobeNewswire Inc
Feb 9, 2021
08:00AM EST  Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Y. Katherine Xu, Ph.D., partner at Decheng Capital, has been appointed to Equilliums board of directors, effective Thursday, February 4, 2021.   GlobeNewswire Inc
Feb 6, 2021
12:42PM EST  The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight   Benzinga
Feb 5, 2021
05:36PM EST  Equillium Announces Closing of $30 Million Registered Direct Offering   GlobeNewswire Inc
Feb 4, 2021
10:53AM EST  Equillium Raises $30M Via Equity, Shares Rally   Benzinga
10:06AM EST  IIROC Trading Resumption - EQ   PR Newswire
08:07AM EST  Equillium Announces Pricing Of $30M Registered Direct Offering At $7/Unit   Benzinga
08:00AM EST  Equillium Announces Pricing of $30 Million Registered Direct Offering   GlobeNewswire Inc
Feb 3, 2021
05:03PM EST  IIROC Trading Halt - EQ   PR Newswire
Jan 22, 2021
08:05AM EST  Equillium Reports Acceptance Of Late-Breaking Abstract For Oral Presentation Of Interim Data From EQUATE Study In Acute GVHD At 2021 TCT Meetings Feb. 8-12   Benzinga
08:00AM EST  Equillium Announces Acceptance of Late-Breaking Abstract for Oral   GlobeNewswire Inc
Jan 5, 2021
08:00AM EST  Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equilliums chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 11, 2021 at 6:00 am EST.   GlobeNewswire Inc
Dec 30, 2020
10:33AM EST  Mid-Morning Market Update: Markets Open Higher; UK Approves AstraZeneca's Coronavirus Vaccine For Emergency Use   Benzinga
Dec 21, 2020
08:00AM EST  Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as   GlobeNewswire Inc
Dec 7, 2020
08:00AM EST  Equillium Presents Translational Data Demonstrating Impact of   GlobeNewswire Inc
Nov 30, 2020
08:26AM EST  10 Biggest Price Target Changes For Monday   Benzinga
08:00AM EST  Reviewpositiveinterim data from the study ofitolizumab for the treatment of acute GVHD and pipeline programs in lupus / lupus nephritis and uncontrolled asthma   GlobeNewswire Inc
06:22AM EST  HC Wainwright & Co. Maintains Buy on Equillium, Lowers Price Target to $12   Benzinga
Nov 25, 2020
08:04AM EST  Equillium Announces Company Will Not Initiate EQUINOX Phase 3 Clinical Trial To Evaluate Itolizumab In Hospitalized Covid-19 Patients   Benzinga
08:00AM EST  Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that due to the rapidly evolving COVID-19 treatment landscape, the company will not initiate the EQUINOX Phase 3 clinical trial to evaluate itolizumab in hospitalized COVID-19 patients at this time.   GlobeNewswire Inc
Nov 11, 2020
01:28PM EST  Yahoo Finance Trending Stocks For Wednesday, Nov. 11, 2020: FPRX, DDOG, FTEK, VXRT, RKT, PLUG, SRNE, REV, GNUS, SPCE, MYO, FUBO, MRNA, PSHG, IMRN, MAPT, LYFT, BRKS, PACB, APD, NKLA, QCOM, MOMO, OASPQ, LMND, COHR, PDD, EQ, MDGS   Benzinga
Nov 10, 2020
04:24PM EST  Equillium Q3 EPS $(0.31) Up From $(0.35) YoY   Benzinga
04:05PM EST  Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2020.   GlobeNewswire Inc
08:35AM EST  Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equilliums chief executive officer and Krishna Polu, M.D., Equilliums chief medical officer, will present at two upcoming investor conferences in November 2020.   GlobeNewswire Inc
Nov 6, 2020
08:39AM EST  Equillium Announces Positive Interim Data From Third Cohort Of Phase 1b Study Of Itolizumab   RTTNews
08:36AM EST  Equillium Announces Positive Interim Data Of Itolizumab In First-Line Treatment Of Acute Graft-Versus-Host Disease;   Benzinga
08:35AM EST  100%overallresponse rate in dose cohort 3 and 80% overall response rate across all cohorts to date   GlobeNewswire Inc
Nov 4, 2020
08:37AM EST  Equillium Reports Co To Present Data At 2020 American College Of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney, Skin Pathology In Preclinical Models Of Systemic Lupus Erythematosus   Benzinga
08:35AM EST  Studiesfurther validateongoing clinicaldevelopment of itolizumab for the treatmentofsystemiclupuserythematosus and lupusnephritis   GlobeNewswire Inc
Oct 30, 2020
10:40AM EDT  Shares of Equillium, Inc. (EQ) are gaining more than 14 percent or $0.86 in Friday's morning trade at $6.86.   RTTNews
08:09AM EDT  The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts   Benzinga
Oct 29, 2020
04:13PM EDT  Equillium Receives FDA Clearance Of COVID-19 IND For Phase 3 Trial   Benzinga
Sep 17, 2020
04:08PM EDT  Equillium Reports Presented New Data On CD6-ALCAM Pathway In Uncontrolled Asthma At European Respiratory Society Congress   Benzinga
04:07PM EDT  Equillium Presented New Data and Insights on the CD6-ALCAM Pathway   GlobeNewswire Inc
Sep 15, 2020
10:11AM EDT  Shares of clinical-stage biotechnology company Equillium, Inc. (EQ) are rising more than 12% Tuesday morning after the company announced that the FDA has provided positive feedback on the company's plans to evaluate its Coronavirus drug candidate.   RTTNews
08:21AM EDT  Equillium Announces Completion Of FDA Pre-IND Meeting For Itolizumab   Benzinga
08:07AM EDT  Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020   GlobeNewswire Inc
Sep 3, 2020
04:07PM EDT  Equillium to Present at H.C. Wainwright 22nd Annual Global   GlobeNewswire Inc
Aug 21, 2020
06:48AM EDT  HC Wainwright & Co. Maintains Buy on Equillium, Lowers Price Target to $22   Benzinga
Aug 18, 2020
04:05PM EDT  Equillium Announces Closing of Public Offering of Common Stock   GlobeNewswire Inc
Aug 14, 2020
08:26AM EDT  The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal   Benzinga
Aug 13, 2020
09:42PM EDT  Equillium Announces Pricing of Public Offering of Common Stock   GlobeNewswire Inc
04:05PM EDT  Equillium Announces Proposed Public Offering; Size, Price Not Disclosed   Benzinga
04:02PM EDT  Equillium Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
Aug 12, 2020
08:41AM EDT  Equillium Q2 EPS $(0.37) Down From $(0.35) YoY   Benzinga
08:37AM EDT  Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the second quarter 2020.   GlobeNewswire Inc
Aug 10, 2020
04:36PM EDT  Equillium Announces Positive Interim Data With Itolizumab In Acute GVHD Study; Says Complete Response Observed In Five Of Seven Patients In First Two Dose Cohorts   Benzinga
04:07PM EDT  Complete response observed in five of seven patients in first two dose cohorts   GlobeNewswire Inc
Jul 20, 2020
05:11AM EDT  80 Biggest Movers From Friday   Benzinga
Jul 17, 2020
05:08AM EDT  64 Biggest Movers From Yesterday   Benzinga
Jul 14, 2020
02:41PM EDT  Mid-Afternoon Market Update: Dow Climbs 400 Points; nCino Shares Jump   Benzinga
12:11PM EDT  Mid-Day Market Update: Dow Rises 1%; Rigel Pharmaceuticals Shares Spike Higher   Benzinga
11:31AM EDT  Mid-Morning Market Update: Markets Mostly Lower; JPMorgan Tops Q2 Views   Benzinga
10:06AM EDT  Morning Market Stats in 5 Minutes   Benzinga
08:19AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
06:27AM EDT  HC Wainwright & Co. Reiterates Buy on Equillium, Raises Price Target to $24   Benzinga
06:10AM EDT  Equillium Inc Files Prospectus Supplement Related To Common Stock Offering Of Up To $150M   Benzinga
05:11AM EDT  80 Biggest Movers From Yesterday   Benzinga
Jul 13, 2020
02:31PM EDT  Mid-Afternoon Market Update: Dow Jumps 400 Points; Equillium Shares Spike Higher   Benzinga
12:01PM EDT  Mid-Day Market Update: Benefytt Technologies Surges Following Acquisition News; NextCure Shares Slide   Benzinga
10:13AM EDT  Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q2 Estimates   Benzinga
10:10AM EDT  Shares of Equillium, Inc. (EQ) nearly triples on Monday morning after the company said a clinical trial demonstrated that itolizumab significantly reduced mortality in patients with COVID-19.   RTTNews
05:30AM EDT  Equillium Announces Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19; Shares Rise 161% Premarket   Benzinga
03:30AM EDT  Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC